Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis

Gilja, O. H.; Halstensen, Alfred; Digranes, Asbjørn; Mylvaganam, Haima; Aksnes, A.; Høiby, E. Arne

doi:10.1128/aac.37.9.2024

Cited by 43 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rifampin is the drug of choice; ciprofloxacin, ofloxacin, minocycline (not in children), and ceftriaxone are good alternatives (167,243,371,420). To prevent reentry of the pathogenic strain into the household after discharge of a patient treated with penicillin, amoxicillin, or chloramphenicol, drugs that do not sterilize the nasopharyngeal mucosa (1), additional prophylaxis before discharge has been suggested (308).…”

Section: Secondary Prophylaxismentioning

confidence: 99%

Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management

Deuren¹,

Brandtzæg²,

Meer³

2000

Clinical Microbiology Reviews

398

236

View full text Add to dashboard Cite

Section: Secondary Prophylaxismentioning

confidence: 99%

Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management

Deuren¹,

Brandtzæg²,

Meer³

2000

Clinical Microbiology Reviews

398

236

View full text Add to dashboard Cite

“…One collection (133 isolates) was obtained in 1987 from military recruits from throughout Norway enrolled in a camp near the city of Stavanger in western Norway (46). The second group of 114 carrier isolates was collected in 1992 from college students in connection with an outbreak of meningococcal disease near the city of Bergen in western Norway (13), and the third group was from randomly selected individuals living near Oslo in 1991 (8). All strains were typed by dot blotting (46) with the specific MAbs listed below.…”

Section: Methodsmentioning

confidence: 99%

Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway

Wedege¹,

Kolberg²,

Delvig³

et al. 1995

Clin Diagn Lab Immunol

Self Cite

View full text Add to dashboard Cite

An increase in B:15:P1.12 meningococci among isolates from patients with Neisseria meningitidis infection in Norway in recent years led to further characterization of such strains. Between 1987 and 1992, B:15:P1.12 strains constituted 9.8% (24 strains) of B:15 isolates. The B:15:P1.12 strains belonged to the electrophoretic type 5 (ET-5) complex, but 17 (71%) strains were a new clone (ET-5c) not found elsewhere in the world. All but one strain of ET-5c were responsible for a localized outbreak of systemic meningococcal disease in western Norway. A novel monoclonal antibody (202,G-12), developed against the unknown variable region 2 on the class 1 protein of one of these strains, bound to 19 of the 15:P1.12 strains, 4 strains bound the subtype P1.13 reference monoclonal antibody MN24H10.75, and the remaining strain showed no reaction. Sequencing of porA genes demonstrated a series of nine threonine residues in the deduced variable region 2 of the latter strain, while four and five threonine residues were found in the corresponding regions of strains reacting with the monoclonal antibodies 202,G-12 and MN24H10.75, respectively. Epitope mapping with synthetic peptides showed that 202,G-12 bound to a sequence of 11 amino acids which included the four threonine residues specific for subtype P1.13a. Immunoglobulin G antibodies against the P1.7,16 subtype protein, induced in volunteers after vaccination with the Norwegian meningococcal vaccine, did not cross-react on immunoblots with the subtype protein of clone ET-5c. Thus, postvaccination class 1 protein antibodies, assumed to be protective, may not be effective against infection with the new clone.

show abstract

“…The efficacy of fluoroquinolones in the chemoprophylaxis of Neisseria meningitides infections has also been studied and available data suggest that a single dose of 400 mg of ofloxacin, in tonsillopharyngeal carriers of Neisseria meningitides, was effective (97.2%) in eradicating carriage on N. meningitides for a period of 33 days, with no case of meningococcal disease occurring after 6 months [76]. Other studies compared the efficacy of ciprofloxacin versus that of rifampin or ceftriaxone in eradicating Neisseria meningitides, showing equal rates of nasopharyngeal eradication (91.1%, 97.7% and 97.6%, respectively) with no differences in side effects [77].…”

Section: Bacterial Meningitismentioning

confidence: 99%

“…The newer fluoroquinolones, particularly gatifloxacin and trovafloxacin, are highly active against Streptococcus pneumoniae even in cases of penicillin or cephalosporin resistance [14,15,70,71]. The antimicrobial activity and pharmacologic behavior of some fluoroquinolones, has promoted clinical trials studying their efficacy in the treatment of children with bacterial meningitis and upper respiratory infections, particularly recurrent otitis media and treatment failure otitis media [72][73][74][75][76][77][78][79][80][81][82][83].…”

Section: Other Infectionsmentioning

confidence: 99%

Fluoroquinolones in Pediatrics

Arguedas¹,

Sierra²,

Soley³

2006

CDTH

View full text Add to dashboard Cite

The fluoroquinolones (FQ) are a group of antimicrobials with a broad spectrum of activity against gram positive and gram negative organisms, intracellular and anaerobic organisms. These antimicrobial agents have excellent oral bioavailability, high tissue penetration, low protein binding and a long elimination half life. The experience with these antibiotics in children has been limited to certain conditions mainly in the treatment of bronchopulmonary exacerbations in children with cystic fibrosis and in the ambulatory treatment of children with fever and neutropenia. Despite the limited use, it is recognize that there are other potential indications for the use of FQ in pediatrics such as for the treatment of children with bacterial meningitis, refractory and recurrent otitis media, pneumonia, multiply resistant salmonellosis and shigellosis and complicated urinary tract infections. Furthermore, the new FQ have shown excellent invitro activity against penicillin-resistant Streptococcus pneumoniae suggesting that these agents may be an attractive alternative for the treatment of conditions that involve these problematic strains. Cartilage toxicity due to FQ had been a major concern however; the previous experience with ciprofloxacin and recently the results from long term (12 months) prospective studies have found no evidence of such a problem in children. Ciprofloxacin was recently approved for the treatment of children with complicated urinary tract infections. If based on the safety and clinical results of ongoing clinical trials, other new FQ are approved for the treatment of other conditions in children, particularly respiratory tract diseases, caution is highly recommended to avoid selection of bacterial resistance.

show abstract

Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis

Cited by 43 publications

References 15 publications

Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management

Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management

Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway

Fluoroquinolones in Pediatrics

Contact Info

Product

Resources

About